| Literature DB >> 32952673 |
Alexandru Gavan1, Sonia Iurian1, Tibor Casian1, Alina Porfire1, Sebastian Porav2, Ioana Voina1, Alexandru Oprea3, Ioan Tomuta1.
Abstract
The study focused on the fluid-bed granulation process of a product with two active pharmaceutical ingredients, intended for coated tablets preparation and further transfer to industrial scale. The work aimed to prove that an accurate control of the critical granulation parameters can level the input material variability and offer a user-friendly process control strategy. Moreover, an in-line Near-Infrared monitoring method was developed, which offered a real time overview of the moisture level along the granulation process, thus a reliable supervision and control process analytical technology (PAT) tool. The experimental design's results showed that the use of apparently interchangeable active pharmaceutical ingredients (APIs) and filler sorts that comply with pharmacopoeial specifications, lead to different end-product critical attributes. By adapting critical granulation parameters (i.e. binder spray rate and atomising pressure) as a function of material characteristics, led to granules with average sizes comprised in a narrow range of 280-320 µm and low non-granulated fraction of under 5%. Therefore, the accurate control of process parameters according to the formulation particularities achieved the maintenance of product within the design space and removed material related variability. To complete the Quality by design (QbD) strategy, despite its limited spectral domain, the microNIR spectrometer was successfully used as a robust PAT monitoring tool that offered a real time overview of the moisture level and allowed the supervision and control of the granulation process.Entities:
Keywords: Design space; Fluid bed granulation; MicroNIR; Process analytical technology; Quality by design; Risk assessment
Year: 2019 PMID: 32952673 PMCID: PMC7486511 DOI: 10.1016/j.ajps.2019.03.003
Source DB: PubMed Journal: Asian J Pharm Sci ISSN: 1818-0876 Impact factor: 6.598
Variables of the experimental design.
| Quantitative independent variables | Levels of variation | Range of variation | ||
|---|---|---|---|---|
| Binder spraying rate (g/min) | 3 | 5–12.5–20 | ||
| Atomising pressure (atm) | 2 | 0.5–0.75 | ||
| Qualitative independent variables | Sort of ingredient | |||
| Paracetamol | 3 | |||
| Ibuprofen | 3 | |||
| Microcrystalline cellulose | 2 | |||
Quality target product profile of granules containing paracetamol and ibuprofen.
| QTPP element | Target | Observations |
|---|---|---|
| Route of administration | Intermediate product for oral solid dosage form preparation | The granules will be further used for coated tablet preparation |
| Dosage form | Granules | |
| Dosage form API content | 32.68% (w/w) paracetamol | |
| 40.22% (w/w) ibuprofen | ||
| Drug product quality attributes | Mean granule size | 280–320 µm |
| Granule size distribution | Gaussian distribution | |
| Granule polydispersity index | < 50% | |
| Moisture content | 2%–4% | |
| Disintegration time | < 7.5 min | |
| Assay | 90%–110% of the declared content of APIs |
Fig. 1Ishikawa diagram highlighting parameters that could have an impact on the final product properties.
Failure mode effects analysis for risk assessment.
| CPP/CMC | Failure mode | Failure effects | Potential causes | Control methods | O | S | D | RPN |
|---|---|---|---|---|---|---|---|---|
| Paracetamol | Changes in API particle size, shape, polymorphism | Variations of granule size, polydispersity index, humidity | Supplier change | Granule size, distribution and moisture content measurements, NIR spectra | 4 | 5 | 3 | 60 |
| Ibuprofen | Changes in API particle size, shape, polymorphism | Variations of granule size, polydispersity index, humidity | Supplier change | Granule size, distribution and moisture content measurements, NIR spectra | 4 | 5 | 3 | 60 |
| Filler | Changes in filler particle size, shape, polymorphism | Variations of granule size, polydispersity index, humidity | Supplier change | Granule size, distribution and moisture content measurements, NIR spectra | 4 | 5 | 3 | 60 |
| Disintegrant | Changes in disintegrant particle size, shape, polymorphism | Variations of granule size, polydispersity index, humidity, disintegration | Supplier change | Granule size, distribution and moisture content measurements, NIR spectra | 4 | 3 | 2 | 24 |
| Disintegration test | ||||||||
| Binder | Changes in binder particle size, shape, disintegration speed | Variations of granule size, polydispersity index, humidity, disintegration | Supplier change | Granule size, distribution and moisture content measurements, NIR spectra | 4 | 2 | 2 | 16 |
| Disintegration test | ||||||||
| Mixing / preheating time / temperature | Homogeneity issues | Variations of granule size, polydispersity index, humidity | Human errors | Granule size, distribution and moisture content measurements, NIR spectra | 4 | 4 | 3 | 48 |
| Variations in the drying rate | Equipment failure | |||||||
| Binder spray rate | Inhomogeneous moistening of the powder blend | Variations of granule size, polydispersity | Human errors | Granule size, distribution and moisture content measurements, NIR spectra | 5 | 4 | 3 | 60 |
| Variations in the drying rate | index, humidity | Equipment failure | ||||||
| Atomising pressure | Inhomogeneous moistening of the powder blend | Variations of granule size, polydispersity | Human errors | Granule size, distribution and moisture content measurements, NIR spectra | 5 | 4 | 3 | 60 |
| Variations in the drying rate | index, humidity | Equipment failure | ||||||
| Inlet air temperature | Variations in the drying rate | Variations of granule size, polydispersity index, humidity | Human errors | Granule size, distribution and moisture content measurements, NIR spectra | 4 | 4 | 3 | 48 |
| Equipment failure | ||||||||
| Drying time/temperature | Variations in the drying rate | Variations of granule size, polydispersity index, humidity | Human errors | Granule size, distribution and moisture content measurements, NIR spectra | 4 | 4 | 3 | 48 |
| Equipment failure | ||||||||
| Inlet air flow rate | Variations in the drying rate | Variations of granule size, polydispersity index, humidity | Human errors | Granule size, distribution and moisture content measurements, NIR spectra | 4 | 4 | 1 | 16 |
| Equipment failure |
Abbreviations: CPP – critical process parameter, CMC – critical material characteristic, O – occurrence, S – severity, D – detectability, RPN – risk priority number.
Fig. 2Scaled and centred coefficient plots – factor influence over the: (A) LOD% at the end of the binder spraying phase; (B) LOD% at the end of the drying process; (C) average size of the granules; (D) the non-granulated fraction.
Fig. 3Scanning electron microscopy micrographs for the 3 studied ibuprofen sorts.
Fig. 4Raw (A) and pre-processed first derivative (B) spectra registered during the performed granulation runs.
Fig. 5LOD% measured vs. NIR predicted values for 3 granulation runs performed with different binder spraying rate. Abbreviations: N11, N14, N32 – experimental runs performed in different conditions, according to the Design of Experiments.
CQAs and results of the optimal granulation process.
| Qualitative independent variables | Pre-set ingredient sort | ||||
|---|---|---|---|---|---|
| Paracetamol | |||||
| Ibuprofen | |||||
| Microcrystalline cellulose | |||||
| Dependent variables (responses) | CQAs | ||||
| Minimum | Target | Maximum | |||
| LOD (%) – 1/3 binder spraying | 5.5 | – | 8.5 | ||
| LOD (%) – 2/3 binder spraying | 10.2 | – | 15.0 | ||
| LOD (%) – end of binder spraying | 13.3 | – | 19.9 | ||
| LOD (%) – 1/3 drying | 9.0 | – | 14.5 | ||
| LOD (%) – 2/3 drying | 4.5 | – | 9.0 | ||
| LOD (%) – end of drying | 2.0 | 3.0 | 4.0 | ||
| Average granule size (µm) | 280 | 300 | 320 | ||
| Non-granulated fraction (%) | minimisation | ||||
| Dependent variables (responses) | Values | ||||
| DoE | NIR | Experimental | |||
| Predicted | Recovered (%) | Predicted | Recovered (%) | ||
| LOD (%) – 1/3 binder spraying | 6.75 | 90.0 | 8.0 | 106.6 | 7.5 |
| LOD (%) – 2/3 binder spraying | 12.1 | 88.9 | 14.2 | 104.4 | 13.6 |
| LOD (%) – end of binder spraying | 15.4 | 97.5 | 15.7 | 99.4 | 15.8 |
| LOD (%) – 1/3 drying | 10.7 | 98.2 | 11.1 | 101.8 | 10.9 |
| LOD (%) – 2/3 drying | 6.5 | 98.5 | 6.5 | 98.5 | 6.6 |
| LOD (%) – end of drying | 2.0 | 80.0 | 2.5 | 100 | 2.5 |
| Average granule size (µm) | 306 | 101.3 | – | 302 | |
| Non-granulated fraction (%) | 4.5 | 104.6 | – | 4.3 | |
Abbreviations: LOD – loss on drying; CQA – critical quality attributes; DoE – design of experiments; NIR – near-infrared.
Fig. 6Design Spaces for granulation processes that provide optimal granules, adapted according to the sort of ibuprofen used in the formulation. (A): Ibuprofen A (Ibu A); Paracetamol (Par C); Microcrystalline cellulose (MCC B); (B): Ibuprofen B (Ibu B); Paracetamol (Par C); Microcrystalline cellulose (MCC B); (C): Ibuprofen C (Ibu C); Paracetamol (Par C); Microcrystalline cellulose (MCC B).
Fig. 7Moisture content measured and predicted along the optimal granulation process.